
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
We are interested in knowing if you feel you can give your patients quality medical care under the constraints of insurance and state and federal laws.
We are interested in knowing if you feel you can give your patients quality medical care under the constraints of insurance and state and federal laws.






